Drugs / TUXOBERTINIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04209465 | Dec 2019 → Sep 2022 | neoplasm | Black Diamond Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TUXOBERTINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650279 ↗ |
| Known as | BDTX-189 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04209465 ↗ |
| Action | Inhibit | “Receptor protein-tyrosine kinase erbB-2 negative allosteric modulator” CHEMBL4650279 ↗1“BDTX-189 is an irreversible, small molecular inhibitor” NCT04209465 ↗ |
| Modality | Small molecule | “BDTX-189 is an irreversible, small molecular inhibitor” NCT04209465 ↗ |
| Route | Oral | “Participants received a daily, oral dose of BDTX-189” NCT04209465 ↗ |
| Target | EGFR | “BDTX-189 is an irreversible, small molecular inhibitor that is highly selective versus wild-type EGFR” NCT04209465 ↗ |
| Target | ERBB2 | “Receptor protein-tyrosine kinase erbB-2 negative allosteric modulator” CHEMBL4650279 ↗ |